Inhibitory kappa B kinases as targets for pharmacological regulation

British Journal of Pharmacology

Volumn 165, Issue 4, 2012, Pages 802-819

  Gamble, Carly ^a   McIntosh, Kathryn ^a   Scott, Rebecca ^a   Ho, Ka Ho ^a   Plevin, Robin ^a   Paul, Andrew ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

inflammation; inhibitory kappa B kinase; kinase inhibitors; nuclear factor kappa B; protein protein interactions

Indexed keywords

2 AMINO 3 CYANO 4 ALKYL 6 (2 HYDROXYPHENYL)PYRIDINE; 2 AMINO 3,5 DIARYLBENZAMIDE; 4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; 4 AMINO (2',3' BITHIOPHENE) 5 CARBOXAMIDE; 4 PHENYL 7 AZAINDOLE DERIVATIVE; 6 ARYL 7 ALKOXYISOQUINOLINE; 6 CHLORO 7 METHOXY 8 (2 METHYLNICOTINAMIDO) BETA CARBOLINE; 6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; ACETYLSALICYLIC ACID; ANTISENSE OLIGONUCLEOTIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FLURBIPROFEN; GEMCITABINE; I KAPPA B KINASE; I KAPPA B KINASE INHIBITOR; IBUPROFEN; IMD 0354; LEFLUNOMIDE; N [3,5 BIS(TRIFLUOROMETHYL)PHENYL] 5 CHLORO 2 HYDROXYBENZAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; SALICYLIC ACID DERIVATIVE; SC 514; SMALL INTERFERING RNA; STEROID; SULINDAC; THREONYLALANYLLEUCYLASPARTYLTRYPTOPHANYLSERYLTRYPTOPHANYLLEUCYLGLUTAMINYLTHREONINE; THREONYLALANYLLEUCYLASPARTYLTRYPTOPHANYLSERYLTRYPTOPHANYLLEUCYLGLUTAMINYLTHREONYLGLUTAMATE; THREONYLTHREONYLLEUCYLASPARTYLTRYPTOPHANYLSERYLTRYPTOPHANYLLEUCYLGLUTAMINYLMETHIONYLGLUTAMATE; TPCA 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; WEDELOLACTONE;

ACUTE PANCREATITIS; ALLERGIC ENCEPHALOMYELITIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; ASTHMA; CARDIAC GRAFT REJECTION; COLITIS; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG RESISTANCE; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; EDEMA; ENZYME ACTIVATION; HUMAN; IC 50; INFLAMMATION; PANCREATITIS; PAW EDEMA; PERITONITIS; PNEUMONIA; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; HUMANS; I-KAPPA B KINASE; INFLAMMATION; NEOPLASMS; NF-KAPPA B; PROTEIN KINASE INHIBITORS;

EID: 84856259390     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01608.x     Document Type: Review

References (196)

1. Adli M, Baldwin AS, (2006). IKK-i/IKKepsilon controls constitutive, cancer cell-associated NF-kappaB activity via regulation of Ser-536 p65/RelA phosphorylation. J Biol Chem 281: 26976-26984. (Pubitemid 44401726)
2. Agarwal A, Das K, Lerner N, Sathe S, Cicek M, Casey G, et al,. (2004). The AKT/I[kappa]B kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-[kappa]B and [beta]-catenin. Oncogene 24: 1021-1031. (Pubitemid 40313879)
3. Agou F, Courtois G, Chiaravalli J, Baleux F, Coic YM, Traincard F, et al,. (2004). Inhibition of NF-kappa B activation by peptides targeting NF-kappa B essential modulator (nemo) oligomerization. J Biol Chem 279: 54248-54257. (Pubitemid 40053162)
4. Alinari L, White VL, Earl CT, Ryan TP, Johnston JS, Dalton JT, et al,. (2009). Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma. MAbs 1: 31-40.
5. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M, (2010). B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464: 302-305.
6. Andreakos E, Smith C, Kiriakidis S, Monaco C, de Martin R, Brennan FM, et al,. (2003). Heterogeneous requirement of IkappaB kinase 2 for inflammatory cytokine and matrix metalloproteinase production in rheumatoid arthritis: implications for therapy. Arthritis Rheum 48: 1901-1912. (Pubitemid 36828685)
7. Anest V, Hanson JL, Cogswell PC, Steinbrecher KA, Strahl BD, Baldwin AS, (2003). A nucleosomal function for I[kappa]B kinase-[alpha] in NF-[kappa]B-dependent gene expression. Nature 423: 659-663. (Pubitemid 36713228)
8. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, et al,. (2005). IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med 11: 191-198. (Pubitemid 40321355)
9. Arun P, Brown MS, Ehsanian R, Chen Z, Van Waes C, (2009). Nuclear NF-κB p65 phosphorylation at serine 276 by protein kinase A contributes to the malignant phenotype of head and neck cancer. Clin Cancer Res 15: 5974-5984.
10. Asamitsu K, Yamaguchi T, Nakata K, Hibi Y, Victoriano A-FB, Imai K, et al,. (2008). Inhibition of human immunodeficiency virus type 1 replication by blocking IkB kinase with noraristeromycin. J Biochem 144: 581-589.
11. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M, (1995). Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270: 286-290.
12. Azuma M, Yamashita T, Aota K, Tamatani T, Sato M, (2001). 5-Fluorouracil suppression of NF-[kappa]B is mediated by the inhibition of I[kappa]B kinase activity in human salivary gland cancer cells. Biochem Biophys Res Commun 282: 292-296. (Pubitemid 32924378)
13. Bannai M, Tokunaga K, Imanishi T, Harihara S, Fujisawa K, Juji T, et al,. (1996). HLA class II alleles in Ainu living in Hidaka District, Hokkaido, northern Japan. Am J Phys Anthropol 101: 1-9. (Pubitemid 26295309)
14. Barre B, Perkins ND, (2007). A cell cycle regulatory network controlling NF-kappaB subunit activity and function. EMBO J 26: 4841-4855. (Pubitemid 350191299)
15. Baxter A, Brough S, Cooper A, Floettmann E, Foster S, Harding C, et al,. (2004). Hit-to-lead studies: the discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors. Bioorg Med Chem Lett 14: 2817-2822. (Pubitemid 38569743)
16. Beaulieu F, Ouellet C, Ruediger EH, Belema M, Qiu Y, Yang X, et al,. (2007). Synthesis and biological evaluation of 4-amino derivatives of benzimidazoquinoxaline, benzimidazoquinoline, and benzopyrazoloquinazoline as potent IKK inhibitors. Bioorg Med Chem Lett 17: 1233-1237.
17. Bednarski BK, Baldwin AS Jr, Kim HJ, (2009). Addressing reported pro-apoptotic functions of NF-kB: targeted inhibition of canonical NF-kB enhances the apoptotic effects of doxorubicin. PLoS ONE 4: e6992.
18. Benito MJ, Murphy E, Murphy EP, van den Berg WB, FitzGerald O, Bresnihan B, (2004). Increased synovial tissue NF-kappa B1 expression at sites adjacent to the cartilage-pannus junction in rheumatoid arthritis. Arthritis Rheum 50: 1781-1787. (Pubitemid 38725090)
19. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Buttarelli M, Jacquemier J, et al,. (2009). How different are luminal A and basal breast cancers? Int J Cancer 124: 1338-1348.
20. Bettermann K, Vucur M, Haybaeck J, Koppe C, Janssen J, Heymann F, et al,. (2010). TAK1 suppresses a NEMO-dependent but NF-[kappa]B-independent pathway to liver cancer. Cancer Cell 17: 481-496.
21. Bogoyevitch M, Arthur PG, (2008). Inhibitors of c-Jun N-terminal kinases-JuNK no more? Biochim Biophys Acta 1784: 76-93.
22. Bonafoux D, Bonar S, Christine L, Clare M, Donnelly A, Guzova J, et al,. (2005). Inhibition of IKK-2 by 2-[(aminocarbonyl)amino]-5-acetylenyl-3- thiophenecarboxamides. Bioorg Med Chem Lett 15: 2870-2875.
23. Bremner P, Heinrich M, (2002). Natural products as targeted modulators of the nuclear factor-kappaB pathway. J Pharm Pharmacol 54: 453-472. (Pubitemid 34308488)
24. Broemer M, Krappmann D, Scheidereit C, (2004). Requirement of Hsp90 activity for I[kappa]B kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-[kappa]B activation. Oncogene 23: 5378-5386. (Pubitemid 39005813)
25. Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U, (1995). Control of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation. Science 267: 1485-1488.
26. Burke JR, Pattoli MA, Gregor KR, Brassil PJ, MacMaster JF, McIntyre KW, et al,. (2003). BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J Biol Chem 278: 1450-1456. (Pubitemid 36801370)
27. Buss H, A, Schmitz ML, Hoffmann E, Resch K, Kracht M, (2004). Constitutive and interleukin-1-inducible phosphorylation of p65 NF-kB at serine 536 is mediated by multiple protein kinases including IkB kinase (IKK)-α, IKKβ, IKKε, TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated interleukin-8 transcription. J Biol Chem 279: 55633-55643. (Pubitemid 40068850)
28. Campbell IK, Gerondakis S, O'Donnell K, Wicks IP, (2000). Distinct roles for the NF-kappaB1 (p50) and c-Rel transcription factors in inflammatory arthritis. J Clin Invest 105: 1799-1806. (Pubitemid 30421761)
29. Cao Y, Bonizzi G, Seagroves TN, Greten FR, Johnson R, Schmidt EV, et al,. (2001). IKK[alpha] provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell 107: 763-775. (Pubitemid 34033669)
30. Carlsen H, Moskaug JO, Fromm SH, Blomhoff R, (2002). In vivo imaging of NF-kappa B activity. J Immunol 168: 1441-1446.
31. Carvalho G, Fabre C, Braun T, Grosjean J, Ades L, Agou F, et al,. (2007). Inhibition of NEMO, the regulatory subunit of the IKK complex, induces apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene 26: 2299-2307. (Pubitemid 46572822)
32. Castro AC, Dang LC, Soucy F, Grenier L, Mazdiyasni H, Hottelet M, et al,. (2003). Novel IKK inhibitors: beta-carbolines. Bioorg Med Chem Lett 13: 2419-2422.
33. Catley MC, Sukkar MB, Chung KF, Jaffee B, Liao SM, Coyle AJ, et al,. (2006). Validation of the anti-inflammatory properties of small-molecule IkappaB kinase (IKK)-2 inhibitors by comparison with adenoviral-mediated delivery of dominant-negative IKK1 and IKK2 in human airways smooth muscle. Mol Pharmacol 70: 697-705. (Pubitemid 44092330)
34. Charalambous MP, Maihofner C, Bhambra U, Lightfoot T, Gooderham NJ, (2003). Upregulation of cyclooxygenase-2 is accompanied by increased expression of nuclear factor-kappa B and I kappa B kinase-alpha in human colorectal cancer epithelial cells. Br J Cancer 88: 1598-1604. (Pubitemid 36713789)
35. Chau T-L, Gioia R, Gatot J-S, Patrascu F, Carpentier I, Chapelle J-P, et al,. (2008). Are the IKKs and IKK-related kinases TBK1 and IKK-epsilon similarly activated? Trends Biochem Sci 33: 171-180.
36. Chen ZJ, Parent L, Maniatis T, (1996). Site-specific phosphorylation of I[kappa]B[alpha] by a novel ubiquitination-dependent protein kinase activity. Cell 84: 853-862. (Pubitemid 26106855)
37. Chen G, Cao P, Goeddel DV, (2002). TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90. Mol Cell 9: 401-410. (Pubitemid 34195564)
38. Chen Z, Ricker JL, Malhotra PS, Nottingham L, Bagain L, Lee TL, et al,. (2008). Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms. Mol Cancer Ther 7: 1949-1960.
39. Chiao PJ, Na R, Niu J, Sclabas GM, Dong Q, Curley SA, (2002). Role of Rel/NF-κB transcription factors in apoptosis of human hepatocellular carcinoma cells. Cancer 95: 1696-1705.
40. Christopher JA, Avitabile BG, Bamborough P, Champigny AC, Cutler GJ, Dyos SL, et al,. (2007). The discovery of 2-amino-3, 5-diarylbenzamide inhibitors of IKK-alpha and IKK-beta kinases. Bioorg Med Chem Lett 17: 3972-3977. (Pubitemid 46924828)
41. Christopher JA, Bamborough P, Alder C, Campbell A, Cutler GJ, Down K, et al,. (2009). Discovery of 6-aryl-7-alkoxyisoquinoline inhibitors of IkappaB kinase-beta (IKK-beta). J Med Chem 52: 3098-3102.
42. Chung CH, Parker JS, Ely K, Carter J, Yi Y, Murphy BA, et al,. (2006). Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-{kappa}B signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res 66: 8210-8218. (Pubitemid 44299189)
43. Czabanka M, Korherr C, Brinkmann U, Vajkoczy P, (2008). Influence of TBK-1 on tumor angiogenesis and microvascular inflammation. Front Biosci 13: 7243-7249.
44. Dai S, Hirayama T, Abbas S, Abu-Amer Y, (2004). The IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J Biol Chem 279: 37219-37222. (Pubitemid 39195425)
45. Danning CL, Illei GG, Hitchon C, Greer MR, Boumpas DT, McInnes IB, (2000). Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum 43: 1244-1256. (Pubitemid 30416309)
46. Dasgupta S, Jana M, Zhou Y, Fung YK, Ghosh S, Pahan K, (2004). Antineuroinflammatory effect of NF-kappaB essential modifier-binding domain peptides in the adoptive transfer model of experimental allergic encephalomyelitis. J Immunol 173: 1344-1354. (Pubitemid 38924314)
47. Dave SH, Tilstra JS, Matsuoka K, Li F, Karrasch T, Uno JK, et al,. (2007). Amelioration of chronic murine colitis by peptide-mediated transduction of the IkappaB kinase inhibitor NEMO binding domain peptide. J Immunol 179: 7852-7859.
48. De Bosscher K, Schmitz ML, Vanden Berghe W, Plaisance S, Fiers W, Haegeman G, (1997). Glucocorticoid-mediated repression of nuclear factor-kappaB-dependent transcription involves direct interference with transactivation. Proc Natl Acad Sci USA 94: 13504-13509. (Pubitemid 28009612)
49. Dejardin E, Droin NM, Delhase M, Haas E, Cao Y, Makris C, et al,. (2002). The lymphotoxin-[beta] receptor induces different patterns of gene expression via two NF-[kappa]B pathways. Immunity 17: 525-535. (Pubitemid 35223540)
50. Descargues P, Sil AK, Karin M, (2008). IKKalpha, a critical regulator of epidermal differentiation and a suppressor of skin cancer. EMBO J 27: 2639-2647.
51. DiDonato J, Mercurio F, Rosette C, Wu-Li J, Suyang H, Ghosh S, et al,. (1996). Mapping of the inducible IkappaB phosphorylation sites that signal its ubiquitination and degradation. Mol Cell Biol 16: 1295-1304.
52. Domingo-Domenech J, Mellado B, Ferrer B, Truan D, Codony-Servat J, Sauleda S, et al,. (2005). Activation of nuclear factor-[kappa]B in human prostate carcinogenesis and association to biochemical relapse. Br J Cancer 93: 1285-1294. (Pubitemid 41679415)
53. Eddy SF, Guo S, Demicco EG, Romieu-Mourez R, Landesman-Bollag E, Seldin DC, et al,. (2005). Inducible IkappaB kinase/IkappaB kinase epsilon expression is induced by CK2 and promotes aberrant nuclear factor-kappaB activation in breast cancer cells. Cancer Res 65: 11375-11383. (Pubitemid 41823949)
54. Egan LJ, Mays DC, Huntoon CJ, Bell MP, Pike MG, Sandborn WJ, et al,. (1999). Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem 274: 26448-26453.
55. Ellis RD, Goodlad JR, Limb GA, Powell JJ, Thompson RP, Punchard NA, (1998). Activation of nuclear factor kappa B in Crohn's disease. Inflamm Res 47: 440-445. (Pubitemid 28532654)
56. Escarcega RO, Fuentes-Alexandro S, Garcia-Carrasco M, Gatica A, Zamora A, (2007). The transcription factor nuclear factor-kappa B and cancer. Clin Oncol (R Coll Radiol) 19: 154-161. (Pubitemid 46172840)
57. Ethridge RT, Hashimoto K, Chung DH, Ehlers RA, Rajaraman S, Evers BM, (2002). Selective inhibition of NF-kappaB attenuates the severity of cerulein-induced acute pancreatitis. J Am Coll Surg 195: 497-505.
58. Field-Smith A, Morgan GJ, Davies FE, (2006). Bortezomib (Velcade trademark) in the treatment of multiple myeloma. Ther Clin Risk Manag 2: 271-279. (Pubitemid 44349502)
59. Fukuyama R, Ng KP, Cicek M, Kelleher C, Niculaita R, Casey G, et al,. (2007). Role of IKK and oscillatory NFκB kinetics in MMP-9 gene expression and chemoresistance to 5-fluorouracil in RKO colorectal cancer cells. Mol Carcinog 46: 402-413. (Pubitemid 46744460)
60. Gao Z, Zhang D, Guo C, (2010). Paclitaxel efficacy is increased by parthenolide via nuclear factor-kappaB pathways in in vitro and in vivo human non-small cell lung cancer models. Curr Cancer Drug Targets 10: 705-715.
61. Garber K, (2006). The second wave in kinase cancer drugs. Nat Biotechnol 24: 127-130. (Pubitemid 43221690)
62. Gasparian AV, Yao YJ, Kowalczyk D, Lyakh LA, Karseladze A, Slaga TJ, et al,. (2002). The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J Cell Sci 115 (Pt 1): 141-151. (Pubitemid 34105537)
63. Gilmore TD, (1999). Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel. Oncogene 18: 6925-6937.
64. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, et al,. (1996). Metastatic prostate cancer in a transgenic mouse. Cancer Res 56: 4096-4102. (Pubitemid 26304996)
65. Gomez AB, MacKenzie C, Paul A, Plevin R, (2005). Selective inhibition of inhibitory kappa B kinase-beta abrogates induction of nitric oxide synthase in lipopolysaccharide-stimulated rat aortic smooth muscle cells. Br J Pharmacol 146: 217-225. (Pubitemid 43079961)
66. Gotoh Y, Nagata H, Kase H, Shimonishi M, Ido M, (2010). A homogeneous time-resolved fluorescence-based high-throughput screening system for discovery of inhibitors of IKK[beta]-NEMO interaction. Anal Biochem 405: 19-27.
67. Grivennikov SI, Greten FR, Karin M, (2010). Immunity, inflammation, and cancer. Cell 140: 883-899.
68. Guo X, Xu B, Pandey S, Goessl E, Brown J, Armesilla AL, et al,. (2010). Disulfiram/copper complex inhibiting NF[kappa]B activity and potentiating cytotoxic effect of gemcitabine on colon and breast cancer cell lines. Cancer Lett 290: 104-113.
69. Gupta SC, Kim JH, Prasad S, Aggarwal BB, (2010a). Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 29: 405-434.
70. Gupta SC, Sundaram C, Reuter S, Aggarwal BB, (2010b). Inhibiting NF-κB activation by small molecules as a therapeutic strategy. Biochim Biophys Acta 1799: 775-787.
71. Han Z, Boyle DL, Manning AM, Firestein GS, (1998). AP-1 and NF-kappaB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 28: 197-208. (Pubitemid 29027651)
72. Hayakawa Y, Maeda S, Nakagawa H, Hikiba Y, Shibata W, Sakamoto K, et al,. (2009). Effectiveness of IκB kinase inhibitors in murine colitis-associated tumorigenesis. J Gastroenterol 44: 935-943.
73. Herrmann O, Baumann B, de Lorenzi R, Muhammad S, Zhang W, Kleesiek J, et al,. (2005). IKK mediates ischemia-induced neuronal death. Nat Med 11: 1322-1329. (Pubitemid 41752913)
74. Hoberg JE, Yeung F, Mayo MW, (2004). SMRT derepression by the IkappaB kinase alpha: a prerequisite to NF-kappaB transcription and survival. Mol Cell 16: 245-255. (Pubitemid 39388839)
75. Hofer-Warbinek R, Schmid JA, Mayer H, Winsauer G, Orel L, Mueller B, et al,. (2004). A highly conserved proapoptotic gene, IKIP, located next to the APAF1 gene locus, is regulated by p53. Cell Death Differ 11: 1317-1325. (Pubitemid 39591777)
76. Hu Y, Baud V, Oga T, Kim KI, Yoshida K, Karin M, (2001). IKK[alpha] controls formation of the epidermis independently of NF-[kappa]B. Nature 410: 710-714. (Pubitemid 32290360)
77. Huynh QK, Boddupalli H, Rouw SA, Koboldt CM, Hall T, Sommers C, et al,. (2000). Characterization of the recombinant IKK1/IKK2 heterodimer. J Biol Chem 275: 25883-25891.
78. Ianaro A, Tersigni M, Belardo G, Di Martino S, Napolitano M, Palmieri G, et al,. (2009). NEMO-binding domain peptide inhibits proliferation of human melanoma cells. Cancer Lett 274: 331-336.
79. Janssens S, Tschopp J, (2006). Signals from within: the DNA-damage-induced NF-κB response. Cell Death Differ 13: 773-784.
80. Jimi E, Aoki K, Saito H, D'Acquisto F, May MJ, Nakamura I, et al,. (2004). Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med 10: 617-624. (Pubitemid 38796853)
81. Jobin C, Bradham CA, Russo MP, Juma B, Narula AS, Brenner DA, et al,. (1999). Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol 163: 3474-3483. (Pubitemid 29431852)
82. Kamon J, Yamauchi T, Muto S, Takekawa S, Ito Y, Hada Y, et al,. (2004). A novel IKKbeta inhibitor stimulates adiponectin levels and ameliorates obesity-linked insulin resistance. Biochem Biophys Res Commun 323: 242-248. (Pubitemid 39200675)
83. Katoh M, (2007). AP1- and NF-kappaB-binding sites conserved among mammalian WNT10B orthologs elucidate the TNFalpha-WNT10B signaling loop implicated in carcinogenesis and adipogenesis. Int J Mol Med 19: 699-703.
84. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, et al,. (2007). Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12: 131-144. (Pubitemid 47208626)
85. Kishore N, Sommers C, Mathialagan S, Guzova J, Yao M, Hauser S, et al,. (2003). A selective IKK-2 inhibitor blocks NF-kB-dependent gene expression in interleukin-1β-stimulated synovial fibroblasts. J Biol Chem 278: 32861-32871. (Pubitemid 37055728)
86. Kobori M, Yang Z, Gong D, Heissmeyer V, Zhu H, Jung YK, et al,. (2003). Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibiting the IKK complex. Cell Death Differ 11: 123-130. (Pubitemid 38111379)
87. Kobori M, Yang Z, Gong D, Heissmeyer V, Zhu H, Jung YK, et al,. (2004). Wedelolactone suppresses LPS-induced caspase-11 expression by directly inhibiting the IKK complex. Cell Death Differ 11: 123-130. (Pubitemid 38111379)
88. Kopp E, Ghosh S, (1994). Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265: 956-959.
89. Korherr C, Gille H, Schäfer R, Koenig-Hoffmann K, Dixelius J, Egland KA, et al,. (2006). Identification of proangiogenic genes and pathways by high-throughput functional genomics: TBK1 and the IRF3 pathway. Proc Natl Acad Sci USA 103: 4240-4245.
90. Kucharczak J, Simmons MJ, Fan Y, Gelinas C, (2003). To be, or not to be: NF-kappaB is the answer-role of Rel/NF-kappaB in the regulation of apoptosis. Oncogene 22: 8961-8982. (Pubitemid 38121698)
91. Lawrence T, Bebien M, Liu GY, Nizet V, Karin M, (2005). IKK[alpha] limits macrophage NF-[kappa]B activation and contributes to the resolution of inflammation. Nature 434: 1138-1143. (Pubitemid 40663493)
92. Lee DF, Hung MC, (2008). Advances in targeting IKK and IKK-related kinases for cancer therapy. Clin Cancer Res 14: 5656-5662.
93. Li N, Karin M, (1998). Ionizing radiation and short wavelength UV activate NF-kB through two distinct mechanisms. Proc Natl Acad Sci USA 95: 13012-13017. (Pubitemid 28509515)
94. Li Z-W, Chu W, Hu Y, Delhase M, Deerinck T, Ellisman M, et al,. (1999). The IKKβ subunit of IkB kinase (IKK) is essential for nuclear factor kB activation and prevention of apoptosis. J Exp Med 189: 1839-1845. (Pubitemid 29272700)
95. Li Q, Lu Q, Bottero V, Estepa G, Morrison L, Mercurio F, et al,. (2005). Enhanced NF-kB activation and cellular function in macrophages lacking IkB kinase 1 (IKK1). Proc Natl Acad Sci USA 102: 12425-12430. (Pubitemid 41266375)
96. Licht-Murava A, Plotkin B, Eisenstein M, Eldar-Finkelman H, (2011). Elucidating substrate and inhibitor binding sites on the surface of GSK-3β and the refinement of a competitive inhibitor. J Mol Biol 408: 366-378.
97. Liddle J, Bamborough P, Barker MD, Campos S, Cousins RP, Cutler GJ, et al,. (2009). 4-Phenyl-7-azaindoles as potent and selective IKK2 inhibitors. Bioorg Med Chem Lett 19: 2504-2508.
98. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J, (1995). Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem 270: 14255-14258.
99. Ling L, Cao Z, Goeddel DV, (1998). NF-kB-inducing kinase activates IKK-α by phosphorylation of Ser-176. Proc Natl Acad Sci USA 95: 3792-3797. (Pubitemid 28173208)
100. Long YM, Chen K, Liu XJ, Xie WR, Wang H, (2009). Cell-permeable Tat-NBD peptide attenuates rat pancreatitis and acinus cell inflammation response. World J Gastroenterol 15: 561-569.
101. Luo J-L, Tan W, Ricono JM, Korchynskyi O, Zhang M, Gonias SL, et al,. (2007). Nuclear cytokine-activated IKKα controls prostate cancer metastasis by repressing Maspin. Nature 446: 690-694. (Pubitemid 46606879)
102. Luqman S, Pezzuto JM, (2010). NFκB: a promising target for natural products in cancer chemoprevention. Phytother Res 24: 949-963.
103. MacMaster JF, Dambach DM, Lee DB, Berry KK, Qiu Y, Zusi FC, et al,. (2003). An inhibitor of IkappaB kinase, BMS-345541, blocks endothelial cell adhesion molecule expression and reduces the severity of dextran sulfate sodium-induced colitis in mice. Inflamm Res 52: 508-511. (Pubitemid 38058225)
104. Malek S, Chen Y, Huxford T, Ghosh G, (2001). IkBα, but not IkBβ, functions as a classical cytoplasmic inhibitor of NF-kB dimers by masking both NF-kB nuclear localization sequences in resting cells. J Biol Chem 276: 45225-45235.
105. Marienfeld RB, Palkowitsch L, Ghosh S, (2006). Dimerization of the I kappa B kinase-binding domain of NEMO is required for tumor necrosis factor alpha-induced NF-kappa B activity. Mol Cell Biol 26: 9209-9219. (Pubitemid 44904417)
106. Massa PE, Li X, Hanidu A, Siamas J, Pariali M, Pareja J, et al,. (2005). Gene expression profiling in conjunction with physiological rescues of IKKα-null cells with wild type or mutant IKKα reveals distinct classes of IKKα/NF-kB-dependent genes. J Biol Chem 280: 14057-14069. (Pubitemid 40517307)
107. Matsushima A, Kaisho T, Rennert PD, Nakano H, Kurosawa K, Uchida D, et al,. (2001). Essential role of nuclear factor (NF)-kB-inducing kinase and inhibitor of kb (IkB) kinase α in NF-kB activation through lymphotoxin β receptor, but not through tumor necrosis factor receptor I. J Exp Med 193: 631-636. (Pubitemid 32539559)
108. Mauro C, Vito P, Mellone S, Pacifico F, Chariot A, Formisano S, et al,. (2003). Role of the adaptor protein CIKS in the activation of the IKK complex. Biochem Biophys Res Commun 309: 84-90. (Pubitemid 36999762)
109. Mauro C, Pacifico F, Lavorgna A, Mellone S, Iannetti A, Acquaviva R, et al,. (2006). ABIN-1 binds to NEMO/IKKγ and co-operates with A20 in inhibiting NF-kB. J Biol Chem 281: 18482-18488. (Pubitemid 44035507)
110. May MJ, D'Acquisto F, Madge LA, Glockner J, Pober JS, Ghosh S, (2000). Selective inhibition of NF-kappa B activation by a peptide that blocks the interaction of NEMO with the Ikappa B kinase complex. Science 289: 1550-1554.
111. May MJ, Marienfeld RB, Ghosh S, (2002). Characterization of the IkB-kinase NEMO binding domain. J Biol Chem 277: 45992-46000. (Pubitemid 35417584)
112. McIntyre KW, Shuster DJ, Gillooly KM, Dambach DM, Pattoli MA, Lu P, et al,. (2003). A highly selective inhibitor of I kappa B kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. Arthritis Rheum 48: 2652-2659. (Pubitemid 37129443)
113. di Meglio P, Ianaro A, Ghosh S, (2005). Amelioration of acute inflammation by systemic administration of a cell-permeable peptide inhibitor of NF-kappaB activation. Arthritis Rheum 52: 951-958. (Pubitemid 40365119)
114. Miller BS, Zandi E, (2001). Complete reconstitution of human IkB kinase (IKK) complex in yeast. J Biol Chem 276: 36320-36326.
115. Mohan S, Konopinski R, Yan B, Centonze VE, Natarajan M, (2009). High glucose-induced IKK-Hsp-90 interaction contributes to endothelial dysfunction. Am J Physiol Cell Physiol 296: C182-C192.
116. van Montfort RL, Workman P, (2009). Structure-based design of molecular cancer therapeutics. Trends Biotechnol 27: 315-328.
117. Murata T, Shimada M, Sakakibara S, Yoshino T, Kadono H, Masuda T, et al,. (2003). Discovery of novel and selective IKK-beta serine-threonine protein kinase inhibitors. Part 1. Bioorg Med Chem Lett 13: 913-918. (Pubitemid 36255566)
118. Murata T, Shimada M, Kadono H, Sakakibara S, Yoshino T, Masuda T, et al,. (2004a). Synthesis and structure-activity relationships of novel IKK-beta inhibitors. Part 2: improvement of in vitro activity. Bioorg Med Chem Lett 14: 4013-4017. (Pubitemid 38844415)
119. Murata T, Shimada M, Sakakibara S, Yoshino T, Masuda T, Shintani T, et al,. (2004b). Synthesis and structure-activity relationships of novel IKK-beta inhibitors. Part 3: orally active anti-inflammatory agents. Bioorg Med Chem Lett 14: 4019-4022. (Pubitemid 38844416)
120. Mustapha S, Kirschner A, De Moissac D, (2000). A direct requirement of NFkappaB for suppression of apoptosis in ventricular myocytes. Am J Physiol 279: H939-H945.
121. Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, Strober W, (1996). Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med 2: 998-1004. (Pubitemid 26306838)
122. Ogawa H, Azuma M, Muto S, Nishioka Y, Honjo A, Tezuka T, et al,. (2011). IkappaB kinase beta inhibitor IMD-0354 suppresses airway remodelling in a Dermatophagoides pteronyssinus-sensitized mouse model of chronic asthma. Clin Exp Allergy 41: 104-115.
123. Olsen LS, Hjarnaa PJ, Latini S, Holm PK, Larsson R, Bramm E, et al,. (2004). Anticancer agent CHS 828 suppresses nuclear factor-kappa B activity in cancer cells through downregulation of IKK activity. Int J Cancer 111: 198-205. (Pubitemid 38924696)
124. O'Mahony A, Lin X, Geleziunas R, Greene WC, (2000). Activation of the heterodimeric Ikappa B kinase alpha (IKKalpha)-IKKbeta complex is directional: IKKalpha regulates IKKbeta under both basal and stimulated conditions. Mol Cell Biol 20: 1170-1178. (Pubitemid 30069237)
125. Onai Y, Suzuki J, Kakuta T, Maejima Y, Haraguchi G, Fukasawa H, et al,. (2004). Inhibition of IkappaB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury. Cardiovasc Res 63: 51-59. (Pubitemid 38759809)
126. Onai Y, Suzuki J, Maejima Y, Haraguchi G, Muto S, Itai A, et al,. (2007). Inhibition of NF-{kappa}B improves left ventricular remodeling and cardiac dysfunction after myocardial infarction. Am J Physiol Heart Circ Physiol 292: H530-H538. (Pubitemid 46105217)
127. Pahl HL, (1999). Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18: 6853-6866.
128. Perkins ND, (2006). Post-translational modifications regulating the activity and function of the nuclear factor κB pathway. Oncogene 25: 6717-6730. (Pubitemid 44657848)
129. Perkins ND, Gilmore TD, (2006). Good cop, bad cop: the different faces of NF-κB. Cell Death Differ 13: 759-772.
130. Podolin PL, Callahan JF, Bolognese BJ, Li YH, Carlson K, Davis TG, et al,. (2005). Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell proliferation. J Pharmacol Exp Ther 312: 373-381. (Pubitemid 40096491)
131. Podolsky DK, (2002). Inflammatory bowel disease. N Engl J Med 347: 417-429. (Pubitemid 34851835)
132. Prajapati S, Tu Z, Yamamoto Y, Gaynor RB, (2006). IKKalpha regulates the mitotic phase of the cell cycle by modulating Aurora A phosphorylation. Cell Cycle 5: 2371-2380. (Pubitemid 44785847)
133. Reddy ST, Grijalva V, Ng C, Hassan K, Hama S, Mottahedeh R, et al,. (2002). Identification of genes induced by oxidized phospholipids in human aortic endothelial cells. Vascul Pharmacol 38: 211-218. (Pubitemid 36398266)
134. Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T, et al,. (1998). Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 115: 357-369. (Pubitemid 28363428)
135. Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Traish AM, Mercurio F, Sonenshein GE, (2001). Roles of IKK kinases and protein kinase CK2 in activation of nuclear factor-kB in breast cancer. Cancer Res 61: 3810-3818. (Pubitemid 32694998)
136. Roshak AK, Jackson JR, McGough K, Chabot-Fletcher M, Mochan E, Marshall LA, (1996). Manipulation of distinct NFkappaB proteins alters interleukin-1beta-induced human rheumatoid synovial fibroblast prostaglandin E2 formation. J Biol Chem 271: 31496-31501. (Pubitemid 26408607)
137. Rothwarf DM, Zandi E, Natoli G, Karin M, (1998). IKK-[gamma] is an essential regulatory subunit of the I[kappa]B kinase complex. Nature 395: 297-300. (Pubitemid 28447557)
138. Rushe M, Silvian L, Bixler S, Chen LL, Cheung A, Bowes S, et al,. (2008). Structure of a NEMO/IKK-associating domain reveals architecture of the interaction site. Structure 16: 798-808. (Pubitemid 351615013)
139. Sakurai H, Chiba H, Miyoshi H, Sugita T, Toriumi W, (1999). IkB kinases phosphorylate NF-kB p65 subunit on serine 536 in the transactivation domain. J Biol Chem 274: 30353-30356.
140. Saxena U, Goldberg IJ, (1994). Endothelial cells and atherosclerosis: lipoprotein metabolism, matrix interactions, and monocyte recruitment. Curr Opin Lipidol 5: 316-322. (Pubitemid 24341340)
141. Schôn M, Wienrich BG, Kneitz S, Sennefelder H, Amschler K, Vôhringer V, et al,. (2008). KINK-1, a novel small-molecule inhibitor of IKKβ, and the susceptibility of melanoma cells to antitumoral treatment. J Natl Cancer Inst 100: 862-875. (Pubitemid 351881954)
142. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr, (1995). Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 270: 283-286.
143. Schmidt C, Peng B, Li Z, Sclabas GM, Fujioka S, Niu J, et al,. (2003). Mechanisms of proinflammatory cytokine-induced biphasic NF-[kappa]B activation. Mol Cell 12: 1287-1300. (Pubitemid 37487935)
144. Schopf L, Savinainen A, Anderson K, Kujawa J, DuPont M, Silva M, et al,. (2006). IKKβ inhibition protects against bone and cartilage destruction in a rat model of rheumatoid arthritis. Arthritis Rheum 54: 3163-3173. (Pubitemid 44622087)
145. Schreiber S, Nikolaus S, Hampe J, (1998). Activation of nuclear factor kappa B inflammatory bowel disease. Gut 42: 477-484. (Pubitemid 28186562)
146. Sen R, Baltimore D, (1986). Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 46: 705-716. (Pubitemid 16020062)
147. Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, et al,. (2001). Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 293: 1495-1499. (Pubitemid 32801552)
148. Sethi G, Sung B, Kunnumakkara AB, Aggarwal BB, (2009). Targeting TNF for treatment of cancer and autoimmunity. Adv Exp Med Biol 647: 37-51.
149. Shangary S, Wang S, (2009). Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 49: 223-241.
150. Shibata W, Maeda S, Hikiba Y, Yanai A, Ohmae T, Sakamoto K, et al,. (2007). Cutting edge: the IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks inflammatory injury in murine colitis. J Immunol 179: 2681-2685.
151. Shimada T, Kawai T, Takeda K, Matsumoto M, Inoue J, Tatsumi Y, et al,. (1999). IKK-i, a novel lipopolysaccharide-inducible kinase that is related to IκB kinases. Int Immunol 11: 1357-1362. (Pubitemid 29355675)
152. Shuto T, Xu H, Wang B, Han J, Kai H, Gu XX, et al,. (2001). Activation of NF-kappa B by nontypeable Hemophilus influenzae is mediated by toll-like receptor 2-TAK1-dependent NIK-IKK alpha/beta-I kappa B alpha and MKK3/6-p38 MAP kinase signaling pathways in epithelial cells. Proc Natl Acad Sci USA 98: 8774-8779. (Pubitemid 32678103)
153. Sil AK, Maeda S, Sano Y, Roop DR, Karin M, (2004). IkappaB kinase-alpha acts in the epidermis to control skeletal and craniofacial morphogenesis. Nature 428: 660-664. (Pubitemid 38524809)
154. Singh S, Shi Q, Bailey ST, Palczewski MJ, Pardee AB, Iglehart JD, et al,. (2007). Nuclear factor-kB activation: a molecular therapeutic target for estrogen receptor negative and epidermal growth factor receptor family receptor positive human breast cancer. Mol Cancer Ther 6: 1973-1982. (Pubitemid 47052487)
155. Sugimoto K, Hanai H, Tozawa K, Aoshi T, Uchijima M, Nagata T, et al,. (2002). Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology 123: 1912-1922. (Pubitemid 35408315)
156. Sugita A, Ogawa H, Azuma M, Muto S, Honjo A, Yanagawa H, et al,. (2009). Antiallergic and anti-inflammatory effects of a novel I kappaB kinase beta inhibitor, IMD-0354, in a mouse model of allergic inflammation. Int Arch Allergy Immunol 148: 186-198.
157. Sweeney C, Li L, Shanmugam R, Bhat-Nakshatri P, Jayaprakasan V, Baldridge LA, et al,. (2004). Nuclear factor-kB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res 10: 5501-5507. (Pubitemid 39100488)
158. Syrovets T, Gschwend E Jr, Büchele B, Laumonnier Y, Zugmaier W, Genze F, et al,. (2005). Inhibition of IκB kinase activity by acetyl-boswellic acids promotes apoptosis in androgen-independent PC-3 prostate cancer cells in vitro and in vivo. J Biol Chem 280: 6170-6180. (Pubitemid 40280102)
159. Tak PP, Smeets TJ, Boyle DL, Kraan MC, Shi Y, Zhuang S, et al,. (1999). p53 overexpression in synovial tissue from patients with early and longstanding rheumatoid arthritis compared with patients with reactive arthritis and osteoarthritis. Arthritis Rheum 42: 948-953. (Pubitemid 29215005)
160. Takeda K, Takeuchi O, Tsujimura T, Itami S, Adachi O, Kawai T, et al,. (1999). Limb and skin abnormalities in mice lacking IKK. Science 284: 313-316. (Pubitemid 129523448)
161. Tanaka M, Fuentes ME, Yamaguchi K, Durnin MH, Dalrymple SA, Hardy KL, et al,. (1999). Embryonic lethality, liver degeneration, and impaired NF-[kappa]B activation in IKK-[beta]-deficient mice. Immunity 10: 421-429. (Pubitemid 29205478)
162. Tanaka A, Konno M, Muto S, Kambe N, Morii E, Nakahata T, et al,. (2005). A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood 105: 2324-2331. (Pubitemid 40387026)
163. Tapia MA, Gonzalez-Navarrete I, Dalmases A, Bosch M, Rodriguez-Fanjul V, Rolfe M, et al,. (2007). Inhibition of the canonical IKK/NF kappa B pathway sensitizes human cancer cells to doxorubicin. Cell Cycle 6: 2284-2292. (Pubitemid 47547707)
164. Tas SW, de Jong EC, Hajji N, May MJ, Ghosh S, Vervoordeldonk MJ, et al,. (2005). Selective inhibition of NF-kappaB in dendritic cells by the NEMO-binding domain peptide blocks maturation and prevents T cell proliferation and polarization. Eur J Immunol 35: 1164-1174. (Pubitemid 40542223)
165. Tegeder I, Pfeilschifter J, Geisslinger G, (2001). Cyclooxygenase- independent actions of cyclooxygenase inhibitors. FASEB J 15: 2057-2072. (Pubitemid 32927924)
166. Thiele K, Bierhaus A, Autschbach F, Hofmann M, Stremmel W, Thiele H, et al,. (1999). Cell specific effects of glucocorticoid treatment on the NF-kappaBp65/IkappaBalpha system in patients with Crohn's disease. Gut 45: 693-704. (Pubitemid 29492142)
167. Tojima Y, Fujimoto A, Delhase M, Chen Y, Hatakeyama S, Nakayama K, et al,. (2000). NAK is an I[kappa]B kinase-activating kinase. Nature 404: 778-782.
168. Torgerson TR, Colosia AD, Donahue JP, Lin YZ, Hawiger J, (1998). Regulation of NF-kappa B, AP-1, NFAT, and STAT1 nuclear import in T lymphocytes by noninvasive delivery of peptide carrying the nuclear localization sequence of NF-kappa B p50. J Immunol 161: 6084-6092. (Pubitemid 28535979)
169. Townsend RM, Postelnek J, Susulic V, McIntyre KW, Shuster DJ, Qiu Y, et al,. (2004). A highly selective inhibitor of IkappaB kinase, BMS-345541, augments graft survival mediated by suboptimal immunosuppression in a murine model of cardiac graft rejection. Transplantation 77: 1090-1094. (Pubitemid 38508928)
170. Tsao PW, Suzuki T, Totsuka R, Murata T, Takagi T, Ohmachi Y, et al,. (1997). The effect of dexamethasone on the expression of activated NF-kappa B in adjuvant arthritis. Clin Immunol Immunopathol 83: 173-178. (Pubitemid 27195937)
171. Tu Z, Prajapati S, Park KJ, Kelly NJ, Yamamoto Y, Gaynor RB, (2006). IKK alpha regulates estrogen-induced cell cycle progression by modulating E2F1 expression. J Biol Chem 281: 6699-6706. (Pubitemid 43847605)
172. Tysnes BB, (2010). Tumor-initiating and -propagating cells: cells that we would like to identify and control. Neoplasia 12: 506-515.
173. Valentine R, Dawson C, Hu C, Shah K, Owen T, Date K, et al,. (2010). Epstein-Barr virus-encoded EBNA1 inhibits the canonical NF-kappaB pathway in carcinoma cells by inhibiting IKK phosphorylation. Mol Cancer 9: 1.
174. Wahl C, Liptay S, Adler G, Schmid RM, (1998). Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 101: 1163-1174. (Pubitemid 28125296)
175. Wen D, Nong Y, Morgan JG, Gangurde P, Bielecki A, Dasilva J, et al,. (2006). A selective small molecule IkappaB kinase beta inhibitor blocks nuclear factor kappaB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells. J Pharmacol Exp Ther 317: 989-1001. (Pubitemid 43764101)
176. Wharry CE, Haines KM, Carroll RG, May MJ, (2009). Constitutive non-canonical NFkappaB signaling in pancreatic cancer cells. Cancer Biol Ther 8: 1567-1576.
177. Wietek C, Cleaver CS, Ludbrook V, Wilde J, White J, Bell DJ, et al,. (2006). IkB kinase β interacts with p52 and promotes transactivation via p65. J Biol Chem 281: 34973-34981. (Pubitemid 46036536)
178. Woronicz JD, Gao X, Cao Z, Rothe M, Goeddel DV, (1997). I{kappa}B kinase-: NF-B activation and complex formation with IB kinase- and NIK. Science 278: 866-870.
179. Wu ZH, Shi Y, Tibbetts RS, Miyamoto S, (2006). Molecular linkage between the kinase ATM and NF-κB signaling in response to genotoxic stimuli. Science 311: 1141-1146.
180. Wu L, Shao L, An N, Wang J, Pazhanisamy S, Feng W, et al,. (2011). IKKβ regulates the repair of DNA double-strand breaks induced by ionizing radiation in MCF-7 breast cancer cells. PLoS ONE 6: e18447.
181. Wullaert A, Bonnet MC, Pasparakis M, (2011). NF-κB in the regulation of epithelial homeostasis and inflammation. Cell Res 21: 146-158.
182. Wyler E, Kaminska M, Coic YM, Baleux F, Veron M, Agou F, (2007). Inhibition of NF-kappaB activation with designed ankyrin-repeat proteins targeting the ubiquitin-binding/oligomerization domain of NEMO. Protein Sci 16: 2013-2022. (Pubitemid 47367124)
183. Xia Y, Padre RC, De Mendoza TH, Bottero V, Tergaonkar VB, Verma IM, (2009). Phosphorylation of p53 by IkappaB kinase 2 promotes its degradation by beta-TrCP. Proc Natl Acad Sci USA 106: 2629-2634.
184. Xiao G, Fong A, Sun SC, (2004). Induction of p100 processing by NF-kappaB-inducing kinase involves docking IkappaB kinase alpha (IKKalpha) to p100 and IKKalpha-mediated phosphorylation. J Biol Chem 279: 30099-30105. (Pubitemid 38937932)
185. Xu Y, Fang F, St Clair DK, Sompol P, Josson S, St Clair WH, (2008). SN52, a novel nuclear factor-kappaB inhibitor, blocks nuclear import of RelB:p52 dimer and sensitizes prostate cancer cells to ionizing radiation. Mol Cancer Ther 7: 2367-2376.
186. Xu G, Lo YC, Li Q, Napolitano G, Wu X, Jiang X, et al,. (2011). Crystal structure of inhibitor of κB kinase β. Nature 472: 325-330.
187. Yamamoto Y, Verma UN, Prajapati S, Kwak Y-T, Gaynor RB, (2003). Histone H3 phosphorylation by IKK-[alpha] is critical for cytokine-induced gene expression. Nature 423: 655-659. (Pubitemid 36713227)
188. Yamaoka S, Courtois G, Bessia C, Whiteside ST, Weil R, Agou F, et al,. (1998). Complementation cloning of NEMO, a component of the I[kappa]B kinase complex essential for NF-[kappa]B activation. Cell 93: 1231-1240. (Pubitemid 28307427)
189. Yamasaki S, Kawakami A, Nakashima T, Nakamura H, Kamachi M, Honda S, et al,. (2001). Importance of NF-kappaB in rheumatoid synovial tissues: in situ NF-kappaB expression and in vitro study using cultured synovial cells. Ann Rheum Dis 60: 678-684. (Pubitemid 32588371)
190. Yang J, Lin Y, Guo Z, Cheng J, Huang J, Deng L, et al,. (2001). The essential role of MEKK3 in TNF-induced NF-[kappa]B activation. Nat Immunol 2: 620-624. (Pubitemid 32677629)
191. Yang J, Pan WH, Clawson GA, Richmond A, (2007). Systemic targeting inhibitor of kappaB kinase inhibits melanoma tumor growth. Cancer Res 67: 3127-3134. (Pubitemid 46724849)
192. Yang L, Cohn L, Zhang DH, Homer R, Ray A, Ray P, (1998). Essential role of nuclear factor kappaB in the induction of eosinophilia in allergic airway inflammation. J Exp Med 188: 1739-1750. (Pubitemid 28516118)
193. Yin MJ, Yamamoto Y, Gaynor RB, (1998). The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396: 77-80. (Pubitemid 28520452)
194. Zetoune FS, Murthy AR, Shao Z, Hlaing T, Zeidler MG, Li Y, et al,. (2001). A20 inhibits NF-[kappa]B activation downstream of multiple MAP3 KINASES and interacts with the I[kappa]B signalosome. Cytokine 15: 282-298. (Pubitemid 34587630)
195. Zhang SQ, Kovalenko A, Cantarella G, Wallach D, (2000). Recruitment of the IKK signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO (IKK[gamma]) upon receptor stimulation. Immunity 12: 301-311.
196. Ziegelbauer K, Gantner F, Lukacs NW, Berlin A, Fuchikami K, Niki T, et al,. (2005). A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity. Br J Pharmacol 145: 178-192. (Pubitemid 40756522)